GlassScriptPhysician profile
Rajendran Alappan
NPI 1225024557
$87,055.91
in general payments reported to CMS, 2019-2025
28 companies · $13K in 2025
The $13K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $7,425 · 2021: $5,589 · 2022: $14K · 2023: $19K · 2024: $3,956 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $10K · Food and Beverage: $3,181 · Travel and Lodging: $1,589 · Education: $216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,904.00 |
| Consulting Fee | $10,360.50 |
| Food and Beverage | $3,180.83 |
| Travel and Lodging | $1,589.08 |
| Education | $216.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $50,105.31 | 2019-2025 | Lokelma, Farxiga |
| Glaxosmithkline, LLC. | $13,838.70 | 2021-2024 | Benlysta, Jesduvroq |
| Akebia Therapeutics INC | $12,886.60 | 2019-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $4,164.58 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,430.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $333.75 | 2022-2025 | |
| Travere Therapeutics, INC. | $310.95 | 2020-2025 | Filspari |
| Opko Pharmaceuticals, LLC | $284.81 | 2022-2024 | Rayaldee |
| Mallinckrodt Hospital Products INC. | $236.08 | 2024-2025 | Acthar |
| Baxter Healthcare | $206.29 | 2019-2024 | Renal - Pd, Renal - Acute |
| Novo Nordisk INC | $170.84 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $166.17 | 2019-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $140.54 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $135.29 | 2019-2024 | Jynarque |
| Horizon Therapeutics Plc | $123.49 | 2019-2023 | Krystexxa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $119.55 | 2019 | |
| Valeritas, INC. | $90.00 | 2019 | |
| Calliditas Therapeutics US INC. | $58.46 | 2022-2025 | Tarpeyo |
| Amarin Pharma, INC. | $56.65 | 2019 | |
| Alnylam Pharmaceuticals INC. | $34.50 | 2022-2024 | Oxlumo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.63 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $23.60 | 2021 | |
| Vifor Pharma, INC. | $22.72 | 2019 | |
| Kyowa Kirin, INC. | $22.37 | 2024 | Crysvita |
| Ardelyx, INC. | $18.71 | 2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $18.15 | 2022 | |
| Shire North American Group INC | $17.49 | 2019 | |
| Fresenius USA Manufacturing, INC. | $15.68 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajendran Alappan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.